ELCC 2019 | Phase III real-world PACIFIC-R trial for NSCLC

Nicolas Girard

Nicolas Girard, MD, PhD, from Claude Bernard University, Lyon, France, gives an overview of the real-world Phase III PACIFIC-R trial (NCT03798535), where post-chemoradiotherapy administration of durvalumab shows promising results in patients with unresectable stage III non-small cell lung cancer (NSCLC). At the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Prof. Girard then discusses the strategies for clinical trial expansion.

Share this video